|Articles|February 12, 2020

NUVISAN and Bayer Create New Research Unit in Berlin

NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. The strategic partnership will lay the foundation for a new research entity to be established by the two companies. The transaction is expected to close mid 2020.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© photon_photo - © photon_photo - stock.adobe.com

NUVISAN and Bayer Create New Research Unit in Berlin

Newsletter

Related Content

Drug Repurposing Through AI-Driven In-Silico Clinical Trials

ACT Brief: CNS Trial Expansion, Vaccine Policy Debate, and New Leadership at FDA

Obesity Trials: Scaling Operations for High-Demand Therapeutics

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

ACT Brief: Targeted Trial Growth, Site Startup Strains, and Leadership Shake-Up at FDA

Trending on Applied Clinical Trials Online

Drug Repurposing Through AI-Driven In-Silico Clinical Trials

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

New ICON Survey Shows Sites Face Growing Delays and Communication Gaps During Study Startup

ACT Brief: FDA’s Agentic AI Rollout, Exercise Interventions for Long COVID, and Patient-Centered Evidence Beyond the Trial

CNS and Autoimmune Trials: Growth and Operational Implications